var data={"title":"Pegylated interferon (peginterferon) alfa-2b: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pegylated interferon (peginterferon) alfa-2b: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6733?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2b-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pegylated interferon (peginterferon) alfa-2b: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2b-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709198\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neuropsychiatric disorders (PegIntron):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including PegIntron, may cause or aggravate fatal or life-threatening neuropsychiatric disorders. Closely monitor patients with periodic clinical and laboratory evaluations. Withdraw patients with persistently severe or worsening signs or symptoms of these conditions from therapy. In many, but not all cases, these disorders resolve after stopping PegIntron therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Autoimmune disorders (PegIntron):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including PegIntron, may cause or aggravate fatal or life-threatening autoimmune disorders. Closely monitor patients with periodic clinical and laboratory evaluations. Withdraw patients with persistently severe or worsening signs or symptoms of these conditions from therapy. In many, but not all cases, these disorders resolve after stopping PegIntron therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ischemic disorders (PegIntron): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including PegIntron, may cause or aggravate fatal or life-threatening ischemic disorders. Closely monitor patients with periodic clinical and laboratory evaluations. Withdraw patients with persistently severe or worsening signs or symptoms of these conditions from therapy. In many, but not all cases, these disorders resolve after stopping PegIntron therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Infectious disorders (PegIntron): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alpha interferons, including PegIntron, may cause or aggravate fatal or life-threatening  infectious disorders. Closely monitor patients with periodic clinical and laboratory evaluations. Withdraw patients with persistently severe or worsening signs or symptoms of these conditions from therapy. In many, but not all cases, these disorders resolve after stopping PegIntron therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ribavirin use (PegIntron):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin may cause birth defects and/or death of the fetus. Take extreme care to avoid pregnancy in women and in female partners of men. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Depression and other neuropsychiatric disorders (Sylatron):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risk of serious depression with suicidal ideation, completed suicides, and other serious neuropsychiatric disorders are increased with alpha interferons, including Sylatron. Permanently discontinue Sylatron in patients with persistently severe or worsening signs or symptoms of depression, psychosis, or encephalopathy. These disorders may not resolve after stopping Sylatron.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206966\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Peg-Intron Redipen Pak 4 [DSC];</li>\n      <li>Peg-Intron Redipen [DSC];</li>\n      <li>PegIntron;</li>\n      <li>Sylatron</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206967\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>PegIntron</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207002\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Biological Response Modulator;</li>\n      <li>\n        Biological Response Modulator;</li>\n      <li>\n        Immunomodulator, Systemic;</li>\n      <li>\n        Interferon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206970\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note</b>\n      <b>: </b>PegIntron Redipen and PegIntron 80 mcg, 120 mcg, and 150 mcg vials have been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma:</b> SubQ: Initial: 6 mcg/kg/week for 8 doses; Maintenance: 3 mcg/kg/week for up to 5 years. <b>Note:</b> Premedicate with acetaminophen (500-1000 mg orally) 30 minutes prior to the first dose and as needed for subsequent doses thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C (CHC): </b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling: </i> <b>Note:</b> Discontinue after 12 weeks in patients with HCV (genotype 1) if HCV RNA does not decrease by at least 2 log (compared to pretreatment) or if detectable HCV RNA present at 24. Discontinuation is also recommended in patients who previously failed therapy (regardless of genotype) if detectable HCV RNA present at 12 or 24 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy with ribavirin: </i> <b>Note:</b> Combination therapy with ribavirin (without the addition of another preferred HCV antiviral agent) is <b>not </b>recommended in HCV treatment guidelines (treatment-naive or treatment-experienced patients) (AASLD/IDSA 2015). Current AASLD/IDSA recommendations do not specify a particular peginterferon (eg, 2a or 2b); however, guideline recommendations are based on clinical trials that used peginterferon alfa-2a.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose (based on an average weekly dose of 1.5 mcg/kg):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;40 kg: 50 mcg once weekly (with ribavirin 800 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 50 kg: 64 mcg once weekly (with ribavirin 800 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">51 to 60 kg: 80 mcg once weekly (with ribavirin 800 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">61 to 65 kg: 96 mcg once weekly (with ribavirin 800 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">66 to 75 kg: 96 mcg once weekly (with ribavirin 1,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 80 kg: 120 mcg once weekly (with ribavirin 1,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">81 to 85 kg: 120 mcg once weekly (with ribavirin 1200 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">86 to 105 kg: 150 mcg once weekly (with ribavirin 1,200 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;105 kg: 1.5 mcg/kg once weekly (with ribavirin 1,400 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment duration: 48 weeks for genotype 1, 24 weeks for genotypes 2 and 3, or 48 weeks for patients who previously failed therapy (regardless of genotype)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Monotherapy: </i> <b>Note:</b> Monotherapy is <b>not </b>recommended in HCV treatment guidelines (treatment-naive or treatment-experienced patients) (AASLD/IDSA 2015). Current AASLD/IDSA recommendations do not specify a particular peginterferon (eg, 2a or 2b); however, guideline recommendations are based on clinical trials that used peginterferon alfa-2a. It is not known whether peginterferon alfa 2b could be used interchangeably. Please refer to AASLD/IDSA clinical practice guidelines for further guidance.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose (based on average weekly dose of 1 mcg/kg):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;45 kg: 40 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">46 to 56 kg: 50 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">57 to 72 kg: 64 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">73 to 88 kg: 80 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">89 to 106 kg: 96 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">107 to 136 kg: 120 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">137 to 160 kg: 150 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment duration: 1 year</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6878383\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2b-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>PegIntron Redipen and PegIntron 80 mcg, 120 mcg, and 150 mcg vials has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C (CHC):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i> Manufacturer labeling:</i> Children 3 to 17 years: SubQ: Combination therapy with ribavirin: 60 mcg/m<sup>2</sup> once weekly; <b>Note:</b> Children who reach their 18th birthday during treatment should remain on the pediatric regimen. Treatment duration is 48 weeks for genotype 1, 24 weeks for genotypes 2 and 3. Discontinue combination therapy in patients with HCV (genotype 1) at 12 weeks if HCV-RNA does not decrease by at least 2 log (compared to pretreatment) or if detectable HCV-RNA present at 24 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206971\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206972\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Chronic hepatitis C:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Peginterferon alfa-2b combination with ribavirin: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Adults: CrCl &lt;50 mL/minute:  Combination therapy with ribavirin is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Children: Serum creatinine &gt;2 mg/dL: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Peginterferon alfa-2b monotherapy:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl 30 to 50 mL/minute: Reduce dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl 10 to 29 mL/minute: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Hemodialysis: Reduce dose by 50% </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Discontinue use if renal function declines during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Melanoma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: Reduce initial dose to 4.5 mcg/kg/week; reduce maintenance dose to 2.25 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup> and ESRD on dialysis: Reduce initial dose to 3 mcg/kg/week; reduce maintenance dose to 1.5 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Hemodialysis: Following a single 1 mcg/kg/ dose, no clinically meaningful amount of peginterferon alfa-2b was removed during hemodialysis.   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206973\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Decompensated liver disease or autoimmune hepatitis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic decompensation or severe hepatic injury during treatment (Child-Pugh score &gt;6 [class B or C]): Discontinue immediately.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207003\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Melanoma:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Discontinue for any of the following:</b> Persistent or worsening severe neuropsychiatric disorders (depression, psychosis, encephalopathy), grade 4 nonhematologic toxicity, new or worsening retinopathy, new-onset ventricular arrhythmia or cardiovascular decompensation, evidence of hepatic injury (severe) or hepatic decompensation (Child-Pugh score &gt;6 [Class B or C]), development of hyper- or hypothyroidism or diabetes that cannot be effectively managed with medication, or inability to tolerate a dose of 1 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Temporarily withhold for any of the following:</b> ANC &lt;500/mm<sup>3</sup>, platelets &lt;50,000/mm<sup>3</sup>, ECOG performance status (PS) &ge;2, nonhematologic toxicity &ge; grade 3</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">May reinitiate at a reduced dose once ANC &ge;500/mm<sup>3</sup>, platelets &ge;50,000/mm<sup>3</sup>, ECOG PS at 0 to 1, and nonhematologic toxicity completely resolved or improved to grade 1.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Reduced dose schedule, Weeks 1 to 8:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">First dose reduction (if prior dose 6 mcg/kg/week): 3 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Second dose reduction (if prior dose 3 mcg/kg/week): 2 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Third dose reduction (if prior dose 2 mcg/kg/week): 1 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Discontinue permanently if unable to tolerate 1 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Reduced dose schedule, Weeks 9 to 260:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">First dose reduction (if prior dose 3 mcg/kg/week): 2 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Second dose reduction (if prior dose 2 mcg/kg/week): 1 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Discontinue permanently if unable to tolerate 1 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>\n        <i>Chronic hepatitis C: </i></b>\n      <b>Dosage adjustment for depression (severity based upon DSM-IV criteria):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Mild depression:</i> No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule. For worsening depression, see &ldquo;Moderate depression&rdquo; or &ldquo;Severe depression&rdquo; below.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Moderate depression: </i> <b>Note:</b> Evaluate once weekly (visit or phone) with an office visit at least every other week. If depression remains stable, consider psychiatric evaluation and continue with reduced dosing. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; continue reduced dosing or return to normal dose. For worsening depression, see &ldquo;Severe depression&rdquo; below. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Children: Decrease peginterferon alfa-2b dose to 40 mcg/m<sup>2</sup>/week, may further decrease to 20 mcg/m<sup>2</sup>/week if needed </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">Peginterferon alfa-2b combination therapy: Refer to adult weight-based dosage reduction with combination therapy for depression below</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">Peginterferon alfa-2b monotherapy: Refer to adult weight-based dosage reduction with monotherapy for depression below</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Severe depression:</i> Discontinue peginterferon alfa-2b and ribavirin permanently. Obtain immediate psychiatric consultation. Utilize followup psychiatric therapy as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>\n        <i>Chronic hepatitis C: </i></b>\n      <b>Dosage adjustment in hematologic toxicity: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemoglobin decrease &ge;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose by 50%; decrease ribavirin dose by 200 mg daily (regardless of the patient&rsquo;s initial dose); monitor and evaluate weekly. If hemoglobin &lt;8.5 g/dL any time after dose reduction  or &lt;12 g/dL after 4 weeks of dose reduction, permanently discontinue both peginterferon alfa-2b and ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemoglobin 8.5 to &lt;10 g/dL and no history of cardiac disease: Decrease ribavirin dose to 12 mg/kg/day; may further reduce to 8 mg/kg/day; no dosage adjustment necessary for  peginterferon alfa-2b.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">WBC 1000 to &lt;1500/mm<sup>3</sup>, neutrophils 500 to &lt;750/mm<sup>3</sup>, or platelets 50,000 to &lt;70,000/mm<sup>3</sup>: Reduce peginterferon alfa-2b dose to 40 mcg/m<sup>2</sup>/week; may further reduce to 20 mcg/m<sup>2</sup>/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemoglobin &lt;8.5 g/dL, WBC &lt;1000/mm<sup>3</sup>, neutrophils &lt;500/mm<sup>3</sup>, or platelets &lt;50,000/mm<sup>3</sup>: Permanently discontinue peginterferon alfa-2b and ribavirin </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemoglobin decrease &ge;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose by 50%; decrease ribavirin dose by 200 mg daily. If hemoglobin &lt;8.5 g/dL any time after dose reduction or  &lt;12 g/dL after 4 weeks of dose reduction, permanently discontinue both peginterferon alfa-2b and ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemoglobin 8.5 to &lt;10 g/dL and no history of cardiac disease: Decrease ribavirin dose by 200 mg daily (patients receiving 1400 mg daily should decrease dose by 400 mg daily [ie, first dose reduction to 1000 mg daily]); may further reduce ribavirin dose by additional 200 mg daily if needed. No dosage adjustment necessary for  peginterferon alfa-2b. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">WBC 1000 to &lt;1500/mm<sup>3</sup>, neutrophils 500 to &lt;750/mm<sup>3</sup>, or platelets 25,000 to &lt;50,000/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">Peginterferon alfa-2b combination therapy: Refer to adult weight-based dosage reduction with combination therapy for hematologic toxicity below.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">Peginterferon alfa-2b monotherapy: Refer to adult weight-based dosage reduction monotherapy for hematologic toxicity below.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemoglobin &lt;8.5 g/dL, WBC &lt;1000/mm<sup>3</sup>, neutrophils &lt;500/mm<sup>3</sup>, or platelets &lt;25,000/mm<sup>3</sup>: Permanently discontinue peginterferon alfa-2b and ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>\n        <i>Chronic hepatitis C: </i></b>\n      <b>Adult weight-based dosage reduction for depression or hematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <i>Peginterferon alfa-2b combination therapy: </i>Initially reduce to average weekly dose of 1 mcg/kg; may further reduce to average weekly dose of 0.5 mcg/kg if needed as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&lt;40 kg: 35 mcg once weekly; may further reduce to 20 mcg once weekly if needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">40 to 50 kg: 45 mcg once weekly; may further reduce to 25 mcg once weekly if needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">51 to 60 kg: 50 mcg once weekly; may further reduce to 30 mcg once weekly if needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">61 to 75 kg: 64 mcg once weekly; may further reduce to 35 mcg once weekly if needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">76 to 85 kg: 80 mcg once weekly; may further reduce to 45 mcg once weekly if needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">86 to 104 kg: 96 mcg once weekly; may further reduce to 50 mcg once weekly if needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">105 to 125 kg: 108 mcg once weekly; may further reduce to 64 mcg once weekly if needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&gt;125 kg: 135 mcg once weekly; may further reduce to 72 mcg once weekly if needed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <i>Peginterferon alfa-2b monotherapy: </i> Reduce to average weekly dose of 0.5 mcg/kg as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&le;45 kg: 20 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">46 to 56 kg: 25 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">57 to 72 kg: 30 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">73 to 88 kg:  40 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">89 to 106 kg: 50 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">107 to 136 kg: 64 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&ge;137 kg: 80 mcg once weekly</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206945\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sylatron: 4 x 200 mcg [DSC], 4 x 300 mcg [DSC] [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peg-Intron Redipen: 50 mcg/0.5 mL [DSC], 80 mcg/0.5 mL [DSC], 120 mcg/0.5 mL [DSC], 150 mcg/0.5 mL [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peg-Intron Redipen Pak 4: 50 mcg/0.5 mL [DSC], 80 mcg/0.5 mL [DSC], 120 mcg/0.5 mL [DSC], 150 mcg/0.5 mL [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PegIntron: 50 mcg/0.5 mL, 80 mcg/0.5 mL [DSC], 120 mcg/0.5 mL [DSC], 150 mcg/0.5 mL [DSC] [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sylatron: 200 mcg, 300 mcg, 600 mcg [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206930\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50801010\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PegIntron Redipen and PegIntron 80 mcg, 120 mcg, and 150 mcg vials have been discontinued in the US for more than 1 year. PegIntron 50 mcg vials will remain available in limited quantities until around June 2018. Contact the Merck National Service Center for additional information: 800-672-6372.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sylatron 600 mcg vials will be discontinued on or near December 2018. Sylatron 200 mcg and 300 mcg vials will be discontinued on or near December 2019. Contact the Merck National Service Center for additional information: 800-672-6372.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874942\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PegIntron, PegIntron Redipen: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103949s5304lbl.pdf#page=28&amp;token=YQoHGEy8Fp6hQI2JQe/REGxyxiK8+jMLeQJLXdT73ZekF43oTc9z32jGSECQSjDFePlKswcEabnxr60EnVS+/Az9pBB8ZSVFfRVkkWOnU7oNqBbgic01ygde6BofTGTG&amp;TOPIC_ID=9976\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103949s5304lbl.pdf#page=28</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sylatron: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103949s5305s5307lbl.pdf#page=13&amp;token=uguNLCdhp56WLYtZnR4Kc61o0et8a94kmGXP+WkpDGFshKtKj91g0WpFjLrkXrXkmzw2//wlNJ/M9s2vYPchFTlpjP046hTF6p14KKHXG2TS3SLGlg9VfXVarDcAMPxW&amp;TOPIC_ID=9976\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103949s5305s5307lbl.pdf#page=13</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206947\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For SubQ administration; rotate injection site; thigh, outer surface of upper arm, and abdomen are preferred injection sites; do not inject near navel or waistline; patients who are thin should only use thigh or upper arm. Do not inject into bruised, infected, irritated, red, or scarred skin. The weekly dose may be administered at bedtime to reduce flu-like symptoms. For the treatment of CHC, the administration volume depends on the patient&rsquo;s weight and the peginterferon concentration used.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206946\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C (CHC):</b> Peg-Intron: Treatment of chronic hepatitis C (CHC) in compensated liver disease:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Combination therapy with ribavirin and an approved hepatitis C virus [HCV] NS3/4A protease inhibitor in adult patients with HCV genotype 1 infection. <b>Note: </b>Regimen is<b> not</b> recommended for hepatitis C virus (HCV) genotype 1 in HCV treatment guidelines (treatment-naive or treatment-experienced) (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Combination therapy with ribavirin in adult patients with HCV genotypes other than 1, in pediatric patients (3 to 17 years), or in patients with HCV genotype 1 with contraindications or intolerance to HCV NS3/4A protease inhibitor use. <b>Note:</b> Combination therapy with ribavirin (<b>without</b> the addition of another preferred HCV antiviral agent) is <b>not </b>recommended for HCV genotypes other than 1 (ie, genotypes 2, 3, 4, 5, or 6) in HCV adult treatment guidelines (treatment-naive or treatment-experienced) (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Monotherapy in adult patients with contraindications or significant intolerance to ribavirin if previously untreated. <b>Note:</b> Monotherapy with peginterferon is <b>not</b> recommended in HCV treatment guidelines (treatment-naive or treatment-experienced) (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: <i>Manufacturer&rsquo;s labeling:</i> Combination therapy with ribavirin provides substantially better response rates than monotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Guideline recommendations:</i></b> Current AASLD/IDSA recommendations do not specify a particular peginterferon (eg, 2a or 2b); however, guideline recommendations are based on clinical trials that used peginterferon alfa-2a (AASLD/IDSA 2015). Hepatitis C treatment guidelines are constantly changing with the advent of new treatment therapies and information; consult current clinical practice guidelines for the most recent treatment recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Melanoma:</b> Sylatron: Adjuvant treatment of melanoma (with microscopic or gross nodal involvement within 84 days of definitive surgical resection, including complete lymphadenectomy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5367712\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Peginterferon alfa-2b may be confused with interferon alfa-2a, interferon alfa-2b, interferon alfa-n3, peginterferon alfa-2a, peginterferon beta-1a</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">PegIntron may be confused with Intron A, Pegasys </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Peginterferon alfa-2b may be confused with interferon alpha multi-subtype which is available in international markets</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206936\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antiviral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Headache (56%), fatigue (including asthenia; &le;52%), depression (29%), anxiety (&le;28%), emotional lability (&le;28%), irritability (&le;28%), insomnia (23%), rigors (23%), dizziness (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Alopecia (22%), pruritus (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Weight Loss (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Nausea (26%), anorexia (20%), diarrhea (18%), abdominal pain (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Viral infection (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local: Inflammation at injection site (47%), injection site reaction (47%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Myalgia (54%), weakness (52%), musculoskeletal pain (28%), arthralgia (23%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Chest pain (6%), flushing (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Lack of concentration (10%), right upper quadrant pain (8%), malaise (7%), nervousness (4%), agitation (2%), suicidal ideation (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Diaphoresis (6%), skin rash (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hypothyroidism (5%), menstrual disease (4%), hyperthyroidism (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Vomiting (7%), dyspepsia (6%), xerostomia (6%), constipation (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Thrombocytopenia (7%), neutropenia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Increased serum ALT (10%), hepatomegaly (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunologic: Antibody development (neutralizing: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local: Pain at injection site (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic: Conjunctivitis (4%), blurred vision (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Pharyngitis (10%), cough (8%), sinusitis (7%), dyspnea (4%), rhinitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antineoplastic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Fatigue (94%), headache (70%), chills (63%), depression (59%, grades 3/4: 7%), dizziness (35%), neuropathy (olfactory) (23%), paresthesia (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Exfoliative rash (36%), alopecia (34%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Weight loss (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Anorexia (69%), nausea (64%), dysgeusia (38%), diarrhea (37%), vomiting (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Increased serum ALT (&le;77%, grades 3/4: &le;11%), increased serum AST (&le;77%, grades 3/4: &le;11%), increased serum alkaline phosphatase (23%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunologic: Antibody development (binding antibodies: 35%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local: Injection site reaction (62%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Myalgia (68%), arthralgia (51%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (75%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Bundle branch block (&le;4%), myocardial infarction (&le;4%), supraventricular cardiac arrhythmia (&le;4%), ventricular tachycardia (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (8%, grades 3/4: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Proteinuria (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Anemia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Dyspnea (6%), cough (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">&lt;1%, postmarketing, and/or case reports: Aggressive behavior, amnesia, anaphylaxis, angina pectoris, angioedema, aphthous stomatitis, aplastic anemia, auditory impairment, bacterial infection, bipolar mood disorder, brain disease (including exacerbations), bronchiolitis obliterans, bronchoconstriction, cardiac arrest, cardiac arrhythmia, cardiomyopathy, cerebrovascular accident, colitis, cytopenia, dehydration, diabetes mellitus, diabetic ketoacidosis, drug dependence (including relapse), drug overdose, dysgeusia, erythema multiforme, exacerbation of autoimmune disease, fungal infection, hallucination, hearing loss, hemorrhagic colitis, homicidal ideation, hyperglycemia, hypersensitivity reaction, hypertension, hypertriglyceridemia, hypotension, immune thrombocytopenia, interstitial nephritis, interstitial pneumonitis, ischemic colitis, leukopenia, lupus-like syndrome, macular edema, mania, migraine, myositis, optic neuritis, palpitations, pancreatitis, papilledema, paresthesia, pericarditis, peripheral neuropathy, pneumonia, psoriasis, pulmonary fibrosis, pulmonary hypertension, pulmonary infiltrates, pure red cell aplasia, reactivation of HBV, renal failure, renal insufficiency (includes increases in serum creatinine), retinal cotton-wool spot, retinal detachment, retinal hemorrhage, retinal thrombosis, retinopathy, rhabdomyolysis, rheumatoid arthritis, sarcoidosis, seizure, sepsis, Stevens-Johnson syndrome, systemic lupus erythematosus, tachycardia, thrombotic thrombocytopenic purpura, thyroiditis, toxic epidermal necrolysis, ulcerative colitis, urticaria, vertigo, vision loss, visual disturbance, Vogt-Koyanagi-Harada syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206950\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (including urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens Johnson syndrome, and toxic epidermal necrolysis) to peginterferon alfa-2b, interferon alfa-2b, other alfa interferons, or any component of the formulation; autoimmune hepatitis; decompensated liver disease (Child-Pugh score &gt;6, classes B and C)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for interferons is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Combination therapy with peginterferon alfa-2b and ribavirin is also contraindicated in pregnancy, women who may become pregnant, males with pregnant partners; hemoglobinopathies (eg, thalassemia major, sickle-cell anemia); renal dysfunction (CrCl &lt;50 mL/minute) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206934\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Causes bone marrow suppression, including potentially severe cytopenias; alfa interferons may (rarely) cause aplastic anemia. Use with caution in patients who are chronically immunosuppressed, with low peripheral blood counts or myelosuppression, including concurrent use of myelosuppressive therapy. Dosage modification may be necessary for hematologic toxicity. Combination therapy with ribavirin may potentiate the neutropenic effects of alfa interferons. When used in combination with ribavirin, an increased incidence of anemia was observed when using ribavirin weight-based dosing, as compared to flat-dose ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Colitis: Ulcerative or hemorrhagic/ischemic colitis has been observed with alfa interferons (within 12 weeks of initiation); discontinue therapy if signs of colitis (abdominal pain, bloody diarrhea, fever) develop; symptoms typically resolve within 1 to 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dental/periodontal disorders: Have been reported with combination therapy; dry mouth may affect teeth and mucous membranes. Instruct patients to brush teeth twice daily; encourage regular dental exams. Rinse mouth thoroughly after vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flu-like symptoms: Interferons are commonly associated with flu-like symptoms. Use with caution in patients with debilitating conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis) and cutaneous reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (rarely) with alfa interferons; prompt discontinuation and management is recommended. Transient rashes do not require interruption of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertriglyceridemia: Has been reported (may result in pancreatitis); periodically monitor and manage with appropriate treatment; consider discontinuing peginterferon if persistent and severe (triglycerides &gt;1000 mg/dL), particularly if combined with symptoms of pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric disorders: <b>[US Boxed Warning]: May cause or aggravate severe depression or other neuropsychiatric adverse events (including suicide and suicidal ideation) in patients with and without a history of psychiatric disorder; monitor closely with clinical evaluations (periodic). Discontinue treatment with worsening or persistently severe signs/symptoms of neuropsychiatric disorders (eg, depression, encephalopathy, psychosis). Many cases resolve upon discontinuation, although some cases may persist.</b> Addiction relapse, aggression, depression, homicidal ideation and suicidal behavior/ideation have been observed with peginterferon alfa-2b; bipolar disorder, encephalopathy, hallucinations, mania, and psychosis have been observed with other alfa interferons. Onset may be delayed (up to 6 months after discontinuation). Higher doses may be associated with the development of encephalopathy (higher risk in elderly patients). Use with caution in patients with a history of psychiatric disorders, including depression or substance abuse history. New or exacerbated neuropsychiatric or substance abuse disorders are best managed with early intervention. Drug screening and periodic health evaluation (including monitoring of psychiatric symptoms) is recommended if initiating treatment in patients with coexisting psychiatric condition or substance abuse disorders. Monitor all patients for evidence of depression and other psychiatric symptoms; patients being treated for melanoma should be monitored for depression and psychiatric symptoms every 3 weeks during the first 8 weeks of treatment and every 6 months thereafter and permanently discontinue treatment if psychiatric symptoms persist, worsen or if suicidal behavior develops. Patients should continue to be monitored for 6 months after completion of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic effects: Ophthalmologic disorders (including decreased visual acuity, blindness, macular edema, retinal hemorrhages, optic neuritis, papilledema, cotton wool spots, retinal detachment [serous], and retinal artery or vein thrombosis) have occurred with peginterferon alfa-2b and/or with other alfa interferons. Prior to start of therapy, ophthalmic exams are recommended for all patients; patients with diabetic or hypertensive retinopathy should have periodic ophthalmic exams during treatment; a complete eye exam should be done promptly in patients who develop ocular symptoms. Permanently discontinue treatment with new or worsening ophthalmic disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Pancreatitis, including fatal cases, has been observed with alfa interferon therapy; withhold treatment for suspected pancreatitis; discontinue therapy for known pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary effects: May cause or aggravate dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis which may result in respiratory failure; may recur upon rechallenge with treatment; monitor closely. Use with caution in patients with existing pulmonary disease (eg, chronic obstructive pulmonary disease). Withhold combination therapy with ribavirin for development of pulmonary infiltrate or pulmonary function impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disease: <b>[US Boxed Warning]: May cause or exacerbate autoimmune disorders; monitor closely with clinical and lab evaluations (periodic); discontinue treatment in patients with worsening or persistently severe signs/symptoms of autoimmune disease; may resolve with discontinuation.</b> Thyroiditis, thrombotic microangiopathy, immune thrombocytopenia, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis have been reported with therapy; use with caution in patients with autoimmune disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or a history of cardiovascular disease; hypotension, arrhythmia, bundle branch block, tachycardia, cardiomyopathy, angina pectoris and MI have been observed with treatment. Patients with pre-existing cardiac abnormalities should have baseline ECGs prior to combination treatment with ribavirin; closely monitor patients with a history of MI or arrhythmia. Patients with a history of significant or unstable cardiac disease should not receive combination treatment with ribavirin. Discontinue treatment (permanently) for new-onset ventricular arrhythmia or cardiovascular decompensation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Diabetes mellitus (including new-onset type I diabetes) and hyperglycemia have been reported; discontinue if diabetes cannot be effectively managed with medication. Use with caution in patients with a history of diabetes mellitus, particularly if prone to DKA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use is contraindicated in patients with hepatic decompensation or autoimmune hepatitis. Discontinue treatment immediately with hepatic decompensation (Child Pugh score &gt;6) or evidence of severe hepatic injury. Patients with chronic hepatitis C (CHC) with cirrhosis and patients coinfected with human immunodeficiency virus (HIV) receiving antiretroviral therapy are at increased risk for hepatic decompensation; monitor closely. A transient increase in ALT (2 to 5 times above baseline) which is not associated with liver dysfunction may occur with peginterferon alfa-2b use (for the treatment of chronic hepatitis C); may continue treatment with close monitoring. Instruct patients to avoid alcohol; may increase hepatic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infectious disorders: <b>[US Boxed Warning]: May cause or aggravate infectious disorders; monitor closely with clinical and lab evaluations (periodic); discontinue treatment in patients with worsening or persistently severe signs/symptoms of infectious disorders; may resolve with discontinuation.</b> Interferon therapy is commonly associated with flu-like symptoms, including fever; rule out other causes/infection with persistent or high fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic disorders: <b>[US Boxed Warning]: May cause or aggravate ischemic and hemorrhagic cerebrovascular events; monitor closely with clinical and lab evaluations (periodic); discontinue treatment in patients with worsening or persistent ischemia; may resolve with discontinuation.</b> Have been reported in patients without risk factors for stroke.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (CrCl &lt;50 mL/minute); monitor closely for signs of interferon toxicity. For the treatment of chronic hepatitis C, dosage adjustments are recommended with monotherapy in patients with moderate to severe impairment; do not use combination therapy with ribavirin in adults with renal dysfunction (CrCl &lt;50 mL/minute); discontinue if serum creatinine &gt;2 mg/dL in children. Dosage adjustment is also recommended when used for the treatment of melanoma. Serum creatinine increases have been reported in patients with renal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Use with caution in patients with thyroid disorders; may cause or aggravate hyper- or hypothyroidism. Discontinue use in patients with thyroid disease who cannot be controlled with medication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Combination therapy with ribavirin: <b>[US Boxed Warning]: Combination treatment with ribavirin may cause birth defects and/or fetal mortality, hemolytic anemia (which may worsen cardiac disease), genotoxicity, mutagenicity, and may possibly be carcinogenic.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Telbivudine: Peripheral neuropathy has been reported with alpha interferons when used in combination with telbivudine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; the potential adverse effects (eg, neuropsychiatric events, cardiac events, systemic effects) may be more pronounced. Encephalopathy has also been observed in primarily elderly patients treated with higher doses of peginterferon alfa-2b. For the treatment of hepatitis, elderly patients generally do not respond to interferon treatment as well as younger patients. When used in combination with ribavirin, closely monitor adults &gt;50 years of age for the development of anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Growth velocity (height and weight) was decreased in children on combination treatment with ribavirin, during the length of treatment. In clinical studies, decreases were noted in weight and height for age z-scores and normative growth curve percentiles. Severely inhibited growth velocity has been noted. Following treatment, rebound growth and weight gain occurred in most patients; however, a small percentage did not. Long-term follow-up data indicate that combination therapy may inhibit growth, resulting in reduced adult height in some patients. Growth should be closely monitored in pediatric patients during therapy and posttreatment until growth catch-up has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Combination therapy with ribavirin may cause birth defects and/or fetal mortality; avoid pregnancy in females and female partners of male patients.</b> Combination therapy with ribavirin is contraindicated in pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product variability: <b>Due to differences in dosage, patients should not change brands of interferon. </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Combination therapy with ribavirin or monotherapy for the treatment of chronic hepatitis C is not a recommended treatment regimen (AASLD/IDSA 2015). Safety and efficacy have not been established in patients who have received organ transplants or are coinfected with HIV or hepatitis B. Patients with significant bridging fibrosis or cirrhosis, genotype 1 infection or who have not responded to prior therapy, including previous pegylated interferon treatment are less likely to benefit from combination therapy with peginterferon alfa-2b and ribavirin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206997\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206938\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9976&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inhibitors): Peginterferon Alfa-2b may increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): Peginterferon Alfa-2b may decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: Peginterferon Alfa-2b may decrease the serum concentration of FLUoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Interferons (Alfa) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: May diminish the therapeutic effect of Peginterferon Alfa-2b.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telbivudine: Peginterferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206940\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C / X in combination with ribavirin (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206952\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use with ribavirin is contraindicated in pregnant women and males whose female partners are pregnant.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>[US Boxed Warning]: Combination therapy with ribavirin may cause birth defects and/or fetal mortality; avoid pregnancy in females and female partners of male patients.</b> Two forms of contraception should be used along with monthly pregnancy tests during combination therapy and for 6 months after therapy has been discontinued. If used in combination with ribavirin, all warnings related to the use of ribavirin and pregnancy and/or contraception should be followed.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Reproduction studies with pegylated interferon alfa have not been conducted. Animal reproduction studies with nonpegylated interferon alfa-2b have demonstrated abortifacient effects. Disruption of the normal menstrual cycle was also observed in animal studies; therefore, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid (Lebon 1982). In vitro administration studies have reported that when administered to the mother, it does not cross the placenta (Waysbort 1993). Case reports of use in pregnant women are limited.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The HHS Perinatal HIV Guidelines do not recommend that peginterferon alfa be used during pregnancy (HHS [perinatal] 2016). Mother-to-child transmission of HCV does not occur if the woman is not viremic, therefore, HCV-infected women of childbearing potential should postpone pregnancy until therapy is complete. Treatment of HCV is not recommended for women who are already pregnant (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206953\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Breast milk samples obtained from a lactating mother prior to and after administration of interferon alfa-2b showed that interferon alfa is present in breast milk and administration of the medication did not significantly affect endogenous levels (Kumar, 2000). Breast-feeding is not linked to the spread of hepatitis C virus (ACOG 2007); however, if nipples are cracked or bleeding, breast-feeding is not recommended (CDC [Workowski] 2015). Mothers coinfected with HIV are discouraged from breast-feeding to decrease potential transmission of HIV (HHS [perinatal] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206942\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline and periodic TSH (for patients being treated for melanoma, obtain baseline within 4 weeks prior to treatment initiation, and then at 3 and 6 months, and every 6 months thereafter during treatment); CBC with differential and platelets; serum chemistries, liver function tests  (for patients with melanoma, monitor serum bilirubin, ALT, AST, alkaline phosphatase, and LDH at 2 and 8 weeks, and 2 and 3 months following initiation, then every 6 months during therapy), renal function, triglycerides; serum glucose or HbA<sub>1c</sub> (for patients with diabetes mellitus). Clinical studies (for combination therapy) tested as follows: CBC (including hemoglobin, WBC, and platelets) and chemistries (including liver function tests and uric acid) measured at weeks 2, 4, 8, and 12, and then every 6 weeks; TSH measured every 12 weeks during treatment. ECG at baseline for patients with pre-existing cardiac abnormalities (for combination therapy with ribavirin).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evaluate for depression and other psychiatric symptoms before and after initiation of therapy; patients being treated for melanoma should be monitored for depression and psychiatric symptoms every 3 weeks during the first eight weeks of treatment and every 6 months thereafter, and continued monitoring for 6 months after the last dose; baseline ophthalmic eye examination; periodic ophthalmic exam in patients with diabetic or hypertensive retinopathy; baseline ECG in patients with cardiac disease; serum glucose or HbA<sub>1c</sub> (for patients with diabetes mellitus). In combination therapy with ribavirin, pregnancy tests (for women of childbearing age who are receiving treatment or who have male partners who are receiving treatment), continue monthly up to 6 months after discontinuation of therapy. In pediatric patients, growth velocity and weight should also be monitored during and periodically after treatment discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Hepatitic C: Serum HCV RNA levels (pretreatment, 12 and 24 weeks after therapy initiation, 24 weeks after completion of therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Alternate recommendations (AASLD/IDSA 2015): Chronic Hepatitis C:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline (within 12 weeks prior to starting antiviral therapy): CBC, INR, hepatic function panel (albumin, total and direct bilirubin, ALT, AST, and alkaline phosphatase), calculated GFR.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline (at any time prior to starting antiviral therapy): HCV genotype and subtype, quantitative HCV viral load.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">During therapy: CBC, serum creatinine, calculated GFR, hepatic function panel (after 4 weeks of therapy and as clinically indicated); quantitative HCV viral load testing (after 4 weeks of therapy and at 12 weeks after completion of therapy). If quantitative HCV viral load is detectable at treatment week 4, repeat testing is recommended after 2 additional weeks of treatment (treatment week 6).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206933\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alpha interferons are a family of proteins, produced by nucleated cells, that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206949\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Increases with chronic dosing </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: CHC: ~40 hours (range: 22 to 60 hours); Melanoma: ~43 to 51 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: CHC: 15 to 44 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~30%); clearance reduced in renal impairment by 17% in moderate dysfunction, 44% in severe dysfunction </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2883315\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (PegIntron Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/0.5 mL (1): $902.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Sylatron Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (1): $2,376.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg (1): $3,564.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (1): $7,128.86</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206954\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alfapeh (UA);</li>\n      <li>Peg Intron (JP, LK, VN);</li>\n      <li>Peg-Intron (AE, BH, CY, JO, KW, LB, LU, LV, QA, SA);</li>\n      <li>PEG-Intron (AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GR, GT, HN, ID, IE, IL, IS, IT, KR, LT, MT, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, RU, SE, SG, SI, SK, SV, TH, TR, TW, VE);</li>\n      <li>Pegintron (BB);</li>\n      <li>PegIntron (HR, HU, RO);</li>\n      <li>Pegtron (MX);</li>\n      <li>Pehintron (UA);</li>\n      <li>ViraFeronPEG (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, HN, IE, IT, MT, NL, PT, RU, SE, SK, TR);</li>\n      <li>Yunitron (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2007, 110(4):941-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/17906043/pubmed\" target=\"_blank\" id=\"17906043\">17906043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org/full-report-view. Updated 2015. Accessed September 16, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bottomley A, Coens C, Suciu S, et al, &ldquo;Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group,&rdquo; <i>J Clin Oncol</i>, 2009, 27(18):2916-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/19433686/pubmed\" target=\"_blank\" id=\"19433686\">19433686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bouwhuis MG, Suciu S, Testori A, et al, &quot;Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies--EORTC 18991,&quot; <i>J Clin Oncol</i>, 2010, 28(14):2460-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/20385998/pubmed\" target=\"_blank\" id=\"20385998\">20385998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dienstag JL and McHutchinson JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo; <i>Gastroenterology</i>, 2006, 130(1):225-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/16401485/pubmed\" target=\"_blank\" id=\"16401485\">16401485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eggermont AM, Suciu S, Santinami M, et al, &quot;Adjuvant Therapy With Pegylated Interferon Alfa-2b versus Observation Alone in Resected Stage III Melanoma: Final Results of EORTC 18991, A Randomised Phase III Trial,&rdquo; <i>Lancet</i>, 2008, 372(9633):117-26<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/18620949/pubmed\" target=\"_blank\" id=\"18620949\">18620949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eggermont AM, Suciu S, Testori A, et al, &ldquo;Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b versus Observation in Resected Stage III Melanoma,&rdquo; <i>J Clin Oncol</i>, 2012, 30(31):3810-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/23008300/pubmed\" target=\"_blank\" id=\"23008300\">23008300</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heathcote EJ, Shiffman ML, Cooksley GE, et al, &ldquo;Peginterferon Alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis,&rdquo; <i>N Engl J Med</i>, 2000, 343:1673-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/11106716/pubmed\" target=\"_blank\" id=\"11106716\">11106716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated April 29, 2016. Accessed May 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar AR, Hale TW, and Moke RE, &ldquo;Transfer of Interferon Alfa Into Human Breast Milk,&rdquo; <i>J Hum Lact</i>, 2000, 16:226-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/11153157/pubmed\" target=\"_blank\" id=\"11153157\">11153157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lebon P, Girard S, Thepot F, et al, &ldquo;The Presence of Alpha-Interferon in Human Amniotic Fluid,&rdquo; <i>J Gen Virol</i>, 1982, 59(Pt 2):393-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/6176680/pubmed\" target=\"_blank\" id=\"6176680\">6176680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McHutchison JG, Lawitz EJ, Shiffman ML, et al, &ldquo;Peginterferon Alfa-2b or Alfa-2a With Ribavirin for Treatment of Hepatitis C Infection,&rdquo; <i>N Engl J Med</i>, 2009, 361(6):580-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/19625712/pubmed\" target=\"_blank\" id=\"19625712\">19625712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    PegIntron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Schering Corp; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poynard T, Colombo M, Bruix J, et al, &ldquo;Peginterferon Alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon Alfa/Ribavirin Therapy,&rdquo; <i>Gastroenterology</i>, 2009, 136(5):1618-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/19208349/pubmed\" target=\"_blank\" id=\"19208349\">19208349</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spieth K, Kaufmann R, Dummer R, et al, &ldquo;Temozolomide Plus Pegylated Interferon Alfa-2b as First-Line Treatment for Stage IV Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group (DeCOG),&rdquo; <i>Ann Oncol</i>, 2008, 19(4):801-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/18178958/pubmed\" target=\"_blank\" id=\"18178958\">18178958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sylatron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waysbort A, Giroux M, Mansat V, et al, &ldquo;Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,&rdquo; <i>Antimicrob Agents Chemother</i>, 1993, 37(6):1232-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/8328774/pubmed\" target=\"_blank\" id=\"8328774\">8328774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9976 Version 177.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709198\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206966\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F206967\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F207002\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F206970\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6878383\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F206971\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F206972\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F206973\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F207003\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206945\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F206930\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50801010\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874942\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F206947\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F206946\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5367712\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206936\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206950\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206934\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F206997\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206938\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206940\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F206952\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F206953\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F206942\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206933\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F206949\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2883315\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F206954\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9976|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2b-patient-drug-information\" class=\"drug drug_patient\">Pegylated interferon (peginterferon) alfa-2b: Patient drug information</a></li><li><a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2b-pediatric-drug-information\" class=\"drug drug_pediatric\">Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information</a></li></ul></div></div>","javascript":null}